GE HealthCare Technologies is expected to announce the acquisition of Sofie Biosciences for $945 million in cash, purchasing the radioactive-substance manufacturer from private equity investor Trilantic North America.
Demand for targeted radiotracers has outpaced supply, creating a genuine competitive advantage for manufacturers who control production capacity. Sofie's isotope manufacturing and distribution operations directly address this bottleneck for GEHC's imaging portfolio.
The deal fits GE HealthCare's post-spinoff capital-allocation discipline—smaller, bolt-on acquisitions rather than transformational moves. At roughly $945 million, the purchase is well within the company's balance-sheet capacity and aligns with how diagnostics peers have historically approached supply-chain consolidation in this niche.
Key catalysts to watch: formal announcement with final terms, the disclosed acquisition multiple, and whether imaging or radiopharma competitors (Lantheus, Eckert & Ziegler, Novartis' radiopharmaceutical division) respond with their own consolidation moves. The vertical integration of isotope supply is the durable strategic benefit here—not near-term earnings accretion.
